An 8-week multi-center, randomized, double-blind, placebo controlled study to evaluate the efficacy, safety and tolerability of pregabalin (150mg-600mg/day) using a flexible dosing schedule in the treatment of subjects with symptoms of neuropathic pain
Latest Information Update: 25 Jan 2021
At a glance
- Drugs Pregabalin (Primary)
- Indications Neuropathic pain
- Focus Therapeutic Use
- Sponsors Pfizer
- 07 May 2011 Updated study details.
- 04 Dec 2007 Status changed from recruiting to completed.
- 21 Oct 2006 New trial record.